

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/247430 A1

(43) International Publication Date
09 December 2021 (09.12.2021)

(51) International Patent Classification:

A61K 38/17 (2006.01) A61P 35/00 (2006.01)
A61K 31/706 (2006.01) A61K 45/00 (2006.01)
A61K 31/122 (2006.01) A61K 45/06 (2006.01)
A61K 31/496 (2006.01) A61P 35/02 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2021/034967

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

28 May 2021 (28.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/033,074 01 June 2020 (01.06.2020) US
63/106,285 27 October 2020 (27.10.2020) US
63/109,083 03 November 2020 (03.11.2020) US
63/114,959 17 November 2020 (17.11.2020) US
63/145,925 04 February 2021 (04.02.2021) US

(71) Applicant: **ALX ONCOLOGY INC.**, [US/US]; 323 Allerton Avenue, South San Francisco, CA 94080 (US).

(72) Inventors: **PONS, Jaume**; c/o ALX ONCOLOGY INC., 866 Malcolm Road, Suite 100, Burlingame, California 94010 (US). **WAN, Hong**; c/o ALX ONCOLOGY INC., 866 Malcolm Road, Suite 100, Burlingame, California 94010 (US). **RANDOLPH, Sophia**; c/o ALX ONCOLOGY INC., 866 Malcolm Road, Suite 100, Burlingame, California 94010 (US).

(74) Agent: **ONUFRYK, Christina**; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: COMBINATION THERAPIES COMPRISING A HYPOMETHYLATION AGENT FOR TREATING CANCER

(57) Abstract: Provided are methods of treating cancer (e.g., a hematological cancer such as myelodysplastic syndrome) that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with a hypomethylating agent (e.g., azacitidine). Also provided are related kits.

WO 2021/247430 A1